Spanish Red Biotech Pipeline

Gilead Sciences

Magrolimab + azacitidine

Type: Biodrugs/ Drugs
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
Indication: 1L higher risk myelodysplastic syndrome
Phase: 3Phase III in Spain, 2Phase II in Spain, 1Phase I in Spain